Roche’s flu drug Xofluza meets primary endpoint in phase III children study

This article was originally published here

The study has showed that Xofluza was well tolerated in children with flu. It also demonstrated that Xofluza is comparable to oseltamivir, a proven effective treatment for children

The post Roche’s flu drug Xofluza meets primary endpoint in phase III children study appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply